top of page

Duncan Hall speaking at Robarts Discovery Accelerated event 16 June


June 16, 2020

Robarts Clinical Trials Presents: Creating value in the emerging landscape of digestive disease drug development

How are GI clinical trials changing? What’s driving change in GI drug development? And, how do we create value in the emerging landscape of digestive disease drug development? These are some of the questions we’ll be addressing.

Duncan Hall, CEO has been invited to speak at an exclusive Robarts event on the 16th June.  He will be sharing the platform alongside senior leaders from Robarts, including: Jeff Smith, CEO; Dr. William Sandborn, MD, Scientific Director: and Dr. Brian Feagan, MD, FRCPC, Scientific Director.  

The event will focus on how GI clinical trials are changing and how Robarts can add value to digestive disease drug development.  Linked to that, Duncan will be presenting on why Risk-Based Quality Management is so important, the problems it solves and the value it drives for sponsors.

If you would like to attend this event, please click here to register.

bottom of page